Ignite Creation Date:
2025-12-25 @ 4:11 AM
Ignite Modification Date:
2025-12-26 @ 3:09 AM
Study NCT ID:
NCT04415320
Status:
UNKNOWN
Last Update Posted:
2020-06-04
First Post:
2020-05-29
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Sponsor:
Betta Pharmaceuticals Co., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-03-21
Start Date Type:
ACTUAL
Primary Completion Date:
2020-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2021-06
Completion Date Type:
ESTIMATED
First Submit Date:
2020-05-29
First Submit QC Date:
None
Study First Post Date:
2020-06-04
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2020-05-29
Last Update Post Date:
2020-06-04
Last Update Post Date Type:
ACTUAL